{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:28:25Z","timestamp":1784341705251,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ijantimicag.2023.106800","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T03:42:57Z","timestamp":1680234177000},"page":"106800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aminopenicillins vs non-aminopenicillins for treatment of enterococcal lower urinary tract infections"],"prefix":"10.1016","volume":"61","author":[{"given":"Jamison E. Montes","family":"de Oca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-2204","authenticated-orcid":false,"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106800_bib0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.diagmicrobio.2008.04.013","article-title":"The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004","volume":"62","author":"Reik","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00001432-200412000-00006","article-title":"Approaches to vancomycin-resistant enterococci","volume":"17","author":"Torres-Viera","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2021.151477","article-title":"Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption","volume":"311","author":"Olearo","year":"2021","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0005","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ijmm.2015.09.005","article-title":"Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy","volume":"305","author":"Lellek","year":"2015","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0006","series-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0007","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: a pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.1.4.358","article-title":"Amoxicillin: in vitro and pharmacological studies","volume":"1","author":"Bodey","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0009","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1128\/AAC.01817-15","article-title":"Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections","volume":"59","author":"Cole","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkg352","article-title":"NAVRESS Group. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North Americsn Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS)","volume":"52","author":"Zhanel","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/ajhp\/zxac068","article-title":"Aminopenicillins for treatment of ampicillin-resistant enterococcal urinary tract infections","volume":"79","author":"Bunnell","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0012","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jac\/4.6.580","article-title":"Absence of bioactive metabolites of ampicillin and amoxycillin in man","volume":"4","author":"Cole","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0013","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.29.4.614","article-title":"Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin","volume":"29","author":"Horber","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2017.06.008","article-title":"Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience","volume":"51","author":"Shah","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0015","first-page":"20","article-title":"Treatment of ampicillin-resistant Enterococcus faecium urinary tract infections","volume":"32","author":"Richey","year":"2015","journal-title":"Fed Pract"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0016","series-title":"CLSI supplement M100","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0017","unstructured":"Slama TG; Infectious Diseases Society of America. Comments Docket #FDA-2012-D0148. Draft guidance for industry on complicated urinary tract infections: developing drugs for treatment. 77 Federal Register 11133. 2012."},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0018","doi-asserted-by":"crossref","first-page":"ofy162","DOI":"10.1093\/ofid\/ofy162","article-title":"Microbiology comment nudge improves pneumonia prescribing","volume":"5","author":"Musgrove","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106800_bib0019","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/ash.2023.1","article-title":"Respiratory culture nudge improves antibiotic prescribing for Moraxella catarrhalis and Haemophilus influenzae lower respiratory tract infections","volume":"3","author":"Arena","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:17Z","timestamp":1760377517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792300081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S092485792300081X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106800","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminopenicillins vs non-aminopenicillins for treatment of enterococcal lower urinary tract infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106800"}}